Men who are overweight or obese when diagnosed with prostate cancer are at greater risk of death after treatment, according to a new study in the December 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study, by Dr. Jason Efstathiou from Massachusetts General Hospital in Boston and colleagues, found that a greater body mass index (BMI) at the time of cancer diagnosis was an independent risk factor for prostate cancer-related death.
Men with “low risk” prostate cancer who miss more than two radiation treatments in an eight week treatment face an increased chance of their cancer recurring. That is the conclusion of a new study examining more than 15 years of data and nearly 1,800 patients treated at Fox Chase Cancer Center in Philadelphia. The results were presented today at the American Society for Therapeutic Radiology and Oncology’s 49th Annual Meeting in Los Angeles.
Prostate cancer patients cut their risk of dying of the disease in half when they receive radiation seed implants (brachytherapy) to treat their cancer, compared to those who don’t receive active treatment (watchful waiting/active surveillance), within six months from being diagnosed with localized prostate cancer, according to a study presented October 31, 2007, at the American Society for Therapeutic Radiology and Oncology’s 49th Annual Meeting in Los Angeles.
An analysis of data involving more than 2,000 patients from 17 U.S. institutions demonstrates that men with high-risk prostate cancer who receive radiation therapy after a prostatectomy were less likely to have a recurrence of disease. What’s more, men whose cancer persists after surgery were less likely to see the cancer spread if they receive radiation (salvage therapy). These are the conclusions of a study presented today at the American Society for Therapeutic Radiology and Oncology’s 49th Annual Meeting in Los Angeles.
Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth. New research has now detected that androgen-synthesizing proteins are present within cancer cells, which suggests that cancer cells may develop the capacity to produce their own androgens.
Men who have prostate cancer are on average four times more likely to suffer a hip fracture, with rates rising to eight times in men aged 50 to 65, according to a study of more than 60,000 men published in the October issue of the urology journal BJU International. Danish researchers looked at 62,865 men aged 50 and over, with an average age of just under 67.
When treating early-stage prostate cancer, intensity modulated radiation therapy spares the bladder significantly more from direct radiation when compared to 3-D conformal proton therapy , but the amount of rectal sparing is similar with both treatments, according to a study released in the October issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.
African-American men are more likely to have their prostate cancer return after treatment, but their disease is no more aggressive when it does recur than that of their white counterparts, according to a study led by Duke Prostate Center researchers.
A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Men with certain scores and patterns based on prostate cancer biopsy were found to be at higher risk of PSA-failure, suggesting that this measurement could help predict the risk of prostate cancer recurrence, according to preliminary research published in the Oct. 3 issue of JAMA.